Koo

In the Life Sciences Interview of 8/26/15 DM states:

"Two years ago we split the company. Many of our compounds went into Zenith Epigenetics Corp., which spun out of Resverlogix to commercialize its epigenetic platform technology. Zenith started programs in oncology and autoimmune diseases. However, during the last few months we have brought some of those compounds back into Resverlogix because of our newer understanding of the mechanism of action."

Chicagoest